134 related articles for article (PubMed ID: 1451349)
1. Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities.
Pereyra-Alfonso S; Solarz GR; Bal de Kier Joffé E
Clin Exp Metastasis; 1992 Nov; 10(6):395-401. PubMed ID: 1451349
[TBL] [Abstract][Full Text] [Related]
2. Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas.
Pereyra-Alfonso S; Haedo A; Bal de Kier Joffé E
Int J Cancer; 1988 Jul; 42(1):59-63. PubMed ID: 3134309
[TBL] [Abstract][Full Text] [Related]
3. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability.
Guerra FK; Eijan AM; Puricelli L; Alonso DF; Bal de Kier Joffé E; Kornblihgtt AR; Charreau EH; Elizalde PV
Int J Cancer; 1996 Mar; 65(6):812-20. PubMed ID: 8631597
[TBL] [Abstract][Full Text] [Related]
4. Impairment of fibrinolysis during the growth of two murine mammary adenocarcinomas.
Alonso DF; Farías EF; Bal de Kier Joffé E
Cancer Lett; 1993 Jul; 70(3):181-7. PubMed ID: 8353814
[TBL] [Abstract][Full Text] [Related]
5. Effects of in vivo culture of murine mammary adenocarcinoma cells on tumor and metastatic growth.
Aguirre Ghiso J; Diament M; D'elia I; Bal de Kier Joffé E; Klein S
Tumour Biol; 1997; 18(1):41-52. PubMed ID: 8989924
[TBL] [Abstract][Full Text] [Related]
6. Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells.
Bal de Kier Joffé E; Alonso DF; Puricelli L
Clin Exp Metastasis; 1991; 9(1):51-6. PubMed ID: 2015717
[TBL] [Abstract][Full Text] [Related]
7. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
8. Prevention of metastasis by inhibition of the urokinase receptor.
Crowley CW; Cohen RL; Lucas BK; Liu G; Shuman MA; Levinson AD
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5021-5. PubMed ID: 8389464
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of urokinase-type plasminogen activator activity during the growth of a murine mammary adenocarcinoma.
Pereyra-Alfonso S; Bal de Kier Joffe E
Int J Cancer; 1989 Feb; 43(2):356-7. PubMed ID: 2492979
[No Abstract] [Full Text] [Related]
10. Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
Marutsuka K; Suzumiya J; Kataoka H; Komada N; Koono M; Sumiyoshi A
Invasion Metastasis; 1991; 11(4):181-91. PubMed ID: 1765431
[TBL] [Abstract][Full Text] [Related]
11. Relationship between circulating plasminogen activators and tumor development in mice.
Colombi M; Rebessi L; Boiocchi M; Barlati S
Cancer Res; 1986 Nov; 46(11):5748-53. PubMed ID: 3093069
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma.
Oka T; Ishida T; Nishino T; Sugimachi K
Cancer Res; 1991 Jul; 51(13):3522-5. PubMed ID: 2054790
[TBL] [Abstract][Full Text] [Related]
13. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
[TBL] [Abstract][Full Text] [Related]
14. Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells.
Gohji K; Nakajima M; Boyd D; Dinney CP; Bucana CD; Kitazana S; Kamidono S; Fidler IJ
Am J Pathol; 1997 Dec; 151(6):1655-61. PubMed ID: 9403716
[TBL] [Abstract][Full Text] [Related]
15. Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
Alonso DF; De Lorenzo MS; Tejera AM; Gomez DE
Oncol Rep; 1998; 5(1):209-12. PubMed ID: 9458324
[TBL] [Abstract][Full Text] [Related]
16. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.
Alonso DF; Farías EF; Ladeda V; Davel L; Puricelli L; Bal de Kier Joffé E
Breast Cancer Res Treat; 1996; 40(3):209-23. PubMed ID: 8883963
[TBL] [Abstract][Full Text] [Related]
17. Enhanced urokinase-type plasminogen activator activity by extracellular matrix protein obtained from highly metastatic human lung adenocarcinoma cell line.
Hagiya Y; Fukao H; Ueshima S; Okada K; Inufusa H; Kamiishi H; Matsuo O
Clin Chim Acta; 1996 Sep; 253(1-2):37-50. PubMed ID: 8879837
[TBL] [Abstract][Full Text] [Related]
18. Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells.
Grant AJ; Ramshaw IA; Badenoch-Jones P; Eichner RD; Hunt NH
Eur J Biochem; 1986 Feb; 154(3):635-41. PubMed ID: 3081343
[TBL] [Abstract][Full Text] [Related]
19. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
20. Malignant myoepithelial cells are associated with the differentiated papillary structure and metastatic ability of a syngeneic murine mammary adenocarcinoma model.
Bumaschny V; Urtreger A; Diament M; Krasnapolski M; Fiszman G; Klein S; Joffé EB
Breast Cancer Res; 2004; 6(2):R116-29. PubMed ID: 14979922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
